{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T17:22:00Z","timestamp":1784222520067,"version":"3.55.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Spanish Ministry of Health ISCIII FIS-FEDER"},{"name":"ISCIII FEDER RedinRen"},{"DOI":"10.13039\/501100004587","name":"ISCIII","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Immunology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.humimm.2018.02.014","type":"journal-article","created":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T23:26:31Z","timestamp":1520465191000},"page":"424-431","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Impact of persistent and cleared preformed HLA DSA on kidney transplant outcomes"],"prefix":"10.1016","volume":"79","author":[{"given":"Dolores","family":"Redondo-Pach\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"P\u00e9rez-S\u00e1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Gimeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Llin\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Y\u00e9lamos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Crespo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.humimm.2018.02.014_b0005","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1681\/ASN.2012070664","article-title":"Donor-specific antibodies adversely affect kidney allograft outcomes","volume":"23","author":"Mohan","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.humimm.2018.02.014_b0010","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/TP.0b013e31827a19cc","article-title":"Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation","volume":"95","author":"Tait","year":"2013","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.humimm.2018.02.014_b0015","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1681\/ASN.2009101065","article-title":"Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation","volume":"21","author":"Lefaucheur","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.humimm.2018.02.014_b0020","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/TP.0b013e31825ace2c","article-title":"Clinical relevance of anti-HLA donor-specific antibodies detected by Luminex assay in the development of rejection after renal transplantation","volume":"94","author":"Caro-Oleas","year":"2012","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.humimm.2018.02.014_b0025","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/j.1600-6143.2012.04013.x","article-title":"Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant","volume":"12","author":"Wiebe","year":"2012","journal-title":"Am. J. Transplant."},{"issue":"2","key":"10.1016\/j.humimm.2018.02.014_b0030","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1681\/ASN.2013101144","article-title":"Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss","volume":"26","author":"Sicard","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"issue":"5","key":"10.1016\/j.humimm.2018.02.014_b0035","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/01.TP.0000438196.30790.66","article-title":"Intermediate-term graft loss after renal transplantation is associated with both donor-specific antibody and acute rejection","volume":"97","author":"Devos","year":"2014","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.humimm.2018.02.014_b0040","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/j.1600-6143.2011.03985.x","article-title":"Pretransplant donor-specific HLA class-I and -II antibodies are associated with an increased risk for kidney graft failure","volume":"12","author":"Otten","year":"2012","journal-title":"Am. J. Transplant."},{"issue":"8","key":"10.1016\/j.humimm.2018.02.014_b0045","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.humimm.2009.04.011","article-title":"Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant","volume":"70","author":"Aubert","year":"2009","journal-title":"Hum. Immunol."},{"issue":"1","key":"10.1016\/j.humimm.2018.02.014_b0050","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/TP.0b013e31821cdf0d","article-title":"Pretransplant IgG subclasses of donor-specific human leukocyte antigen antibodies and development of antibody-mediated rejection","volume":"92","author":"H\u00f6nger","year":"2011","journal-title":"Transplantation"},{"issue":"13","key":"10.1016\/j.humimm.2018.02.014_b0055","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1302506","article-title":"Complement-binding anti-HLA antibodies and kidney-allograft survival","volume":"369","author":"Loupy","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"1\u20134","key":"10.1016\/j.humimm.2018.02.014_b0060","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.trim.2013.07.002","article-title":"Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter?","volume":"29","author":"Crespo","year":"2013","journal-title":"Transpl. Immunol."},{"key":"10.1016\/j.humimm.2018.02.014_b0065","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/ajt.14107","article-title":"The Banff 2015 kidney meeting report: current challenges in rejection classification and prospects for adopting molecular pathology","volume":"17","author":"Loupy","year":"2017","journal-title":"Am. J. Transplant."},{"issue":"3","key":"10.1016\/j.humimm.2018.02.014_b0070","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/ajt.13010","article-title":"Circulating NK-cell subsets in renal allograft recipients with anti-HLA donor-specific antibodies","volume":"15","author":"Crespo","year":"2015","journal-title":"Am. J. Transplant."},{"issue":"11","key":"10.1016\/j.humimm.2018.02.014_b0075","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1093\/ndt\/gfw223","article-title":"Impact of the Banff 2013 classification on the diagnosis of suspicious versus conclusive late antibody-mediated rejection in allografts without acute dysfunction","volume":"31","author":"Gimeno","year":"2016","journal-title":"Nephrol. Dial. Transplant."},{"issue":"3","key":"10.1016\/j.humimm.2018.02.014_b0080","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1600-6143.2010.03421.x","article-title":"Outcome of patients with preformed donor-specific antibodies following alemtuzumab induction and tacrolimus monotherapy","volume":"11","author":"Willicombe","year":"2011","journal-title":"Am. J. Transplant."},{"issue":"3","key":"10.1016\/j.humimm.2018.02.014_b0085","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/ndt\/gfr429","article-title":"Clinical relevance of HLA donor-specific antibodies detected by single antigen assay in kidney transplantation","volume":"27","author":"Caro-Oleas","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"issue":"2","key":"10.1016\/j.humimm.2018.02.014_b0090","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.trim.2015.01.002","article-title":"Analysis of preformed donor-specific anti-HLA antibodies characteristics for prediction of antibody-mediated rejection in kidney transplantation","volume":"32","author":"Malheiro","year":"2015","journal-title":"Transpl. Immunol."},{"issue":"6","key":"10.1016\/j.humimm.2018.02.014_b0095","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.humimm.2016.04.010","article-title":"Clinically relevant threshold of preformed donor-specific anti-HLA antibodies in kidney transplantation","volume":"77","author":"Salvad\u00e9","year":"2016","journal-title":"Hum. Immunol."},{"issue":"8","key":"10.1016\/j.humimm.2018.02.014_b0100","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.humimm.2009.04.018","article-title":"Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival","volume":"70","author":"Vlad","year":"2009","journal-title":"Hum. Immunol."},{"issue":"3","key":"10.1016\/j.humimm.2018.02.014_b0105","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1399-0039.2009.01283.x","article-title":"Clinical relevance of Luminex donor-specific crossmatches: data from 165 renal transplants","volume":"74","author":"Billen","year":"2009","journal-title":"Tissue Antigens"},{"issue":"11","key":"10.1016\/j.humimm.2018.02.014_b0110","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1097\/TP.0b013e3181a5e034","article-title":"Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads","volume":"87","author":"Amico","year":"2009","journal-title":"Transplantation"},{"issue":"10","key":"10.1016\/j.humimm.2018.02.014_b0115","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/ki.2010.556","article-title":"Surveillance of alloantibodies after transplantation identifies the risk of chronic rejection","volume":"79","author":"Kimball","year":"2011","journal-title":"Kidney Int."},{"issue":"10","key":"10.1016\/j.humimm.2018.02.014_b0120","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1097\/TP.0000000000000191","article-title":"Pretransplant immunologic risk assessment of kidney transplant recipients with donor-specific anti-human leukocyte antigen antibodies","volume":"98","author":"Marfo","year":"2014","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.humimm.2018.02.014_b0125","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/tri.12864","article-title":"Pre-existing donor-specific antibodies are detrimental to kidney allograft only when persistent after transplantation","volume":"30","author":"Caillard","year":"2017","journal-title":"Transpl. Int."},{"key":"10.1016\/j.humimm.2018.02.014_b0130","doi-asserted-by":"crossref","DOI":"10.1111\/ajt.13848","article-title":"Clinical significance of pre-transplant donor specific antibodies in the setting of negative cell-based flow cytometry crossmatching in kidney transplant recipients","author":"Adebiyi","year":"2016","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.humimm.2018.02.014_b0135","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1097\/TP.0b013e3181da1cc3","article-title":"Combined posttransplant prophylactic IVIg\/Anti-CD 20\/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study","volume":"89","author":"Loupy","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.humimm.2018.02.014_b0140","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/j.1600-6143.2011.03467.x","article-title":"Donor-directed MHC class I antibody is preferentially cleared from sensitized recipients of combined liver\/kidney transplants","volume":"11","author":"Dar","year":"2011","journal-title":"Am. J. Transplant."},{"issue":"10","key":"10.1016\/j.humimm.2018.02.014_b0145","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1111\/j.1600-6143.2007.01944.x","article-title":"Renal transplantation in patients with pre-transplant donor-specific antibodies and negative flow cytometry crossmatches","volume":"7","author":"Patel","year":"2007","journal-title":"Am. J. Transplant."},{"issue":"8","key":"10.1016\/j.humimm.2018.02.014_b0150","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1097\/TP.0b013e31816b1c37","article-title":"Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: are they relevant?","volume":"85","author":"Gupta","year":"2008","journal-title":"Transplantation"},{"issue":"7","key":"10.1016\/j.humimm.2018.02.014_b0155","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1681\/ASN.2014040399","article-title":"Subclinical rejection phenotypes at 1 year post-transplant and outcome of kidney allografts","volume":"26","author":"Loupy","year":"2015","journal-title":"J. Am. Soc. Nephrol."}],"container-title":["Human Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0198885918300533?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0198885918300533?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T11:51:16Z","timestamp":1759319476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0198885918300533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0198885918300533"],"URL":"https:\/\/doi.org\/10.1016\/j.humimm.2018.02.014","relation":{},"ISSN":["0198-8859"],"issn-type":[{"value":"0198-8859","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of persistent and cleared preformed HLA DSA on kidney transplant outcomes","name":"articletitle","label":"Article Title"},{"value":"Human Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humimm.2018.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}